Alnylam Pharmaceuticals, Inc. (ALNY)
333.39
-6.02
(-1.77%)
USD |
NASDAQ |
Apr 15, 16:00
333.50
+0.11
(+0.03%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (Quarterly) : 372.22M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 3.133B |
| Eli Lilly & Co. | 3.802B |
| Ionis Pharmaceuticals, Inc. | 279.36M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Sarepta Therapeutics, Inc. | 319.50M |